Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies.
about
Substrate mediated enzyme prodrug therapyBiodistribution of HuCC49DeltaCH2-beta-galactosidase in colorectal cancer xenograft model.Magnetic tumor targeting of β-glucosidase immobilized iron oxide nanoparticles.Synthesis, biological evaluation, and live cell imaging of novel fluorescent duocarmycin analogs.Optical imaging of targeted β-galactosidase in brain tumors to detect EGFR levelsAntibody-enzyme fusion proteins for cancer therapy.Novel 19 F-MRS β-galactosidase reporter molecules incorporated nitrogen mustard analogues.Photoactivatable prodrugs of highly potent duocarmycin analogues for a selective cancer therapy.The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy.Duocarmycin analogues target aldehyde dehydrogenase 1 in lung cancer cells.A galactosidase-responsive "trojan horse" for the selective targeting of folate receptor-positive tumor cells.A novel GAP460 biopolymer for use as a carrier in drug-delivery applications.Cytosolic delivery of large proteins using nanoparticle-stabilized nanocapsules.pH-sensitive pHluorins as a molecular sensor for in situ monitoring of enzyme-catalyzed prodrug activation.The two faces of potent antitumor duocarmycin-based drugs: a structural dissection reveals disparate motifs for DNA versus aldehyde dehydrogenase 1 affinity.Biocatalytic polymer coatings: on-demand drug synthesis and localized therapeutic effect under dynamic cell culture conditions.
P2860
Q28485159-3DED78C8-4839-46D8-B210-84130F83C4BEQ33625341-BC04BFB4-A743-4A60-9D71-0D6A52B0DBAEQ33688825-4877F6C7-65C2-4308-83FF-010F60CE7EA9Q34480712-F4AC2477-B6E8-441E-9EF7-B6EB2C255233Q35624259-B6BD3F17-E0B8-487E-9B22-FE276C538BCEQ37842324-D5A3FFE6-8B5B-4740-B7CC-260F606FE70EQ38831996-B3C7191D-8FB1-4502-89F9-D655F821C3F1Q39229406-7C228E46-CD5D-4782-B947-27D31652540CQ39274501-57E05101-57CC-4FBB-B04B-1AF8866F661DQ39396571-E2877D54-FEFA-41E0-B468-3180544238EDQ39569531-2BB27C75-59E0-45C9-B5B3-F06A16D313E5Q39638742-45AF3908-757E-45FB-9E17-86C76FE9D2C9Q42801662-B4FEA958-DA88-45ED-8503-E5783EAFDF00Q50227405-930155E6-4BF1-43C4-95EA-3754CC92E3C7Q50987490-4663D2B8-FAE2-4A2F-9A9D-9DDFF6A51576Q51762759-99C9E4C2-CE0B-4748-B5AA-E3F7A5884EB8
P2860
Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Antibody-directed enzyme prodr ...... ugs and monoclonal antibodies.
@en
Antibody-directed enzyme prodr ...... ugs and monoclonal antibodies.
@nl
type
label
Antibody-directed enzyme prodr ...... ugs and monoclonal antibodies.
@en
Antibody-directed enzyme prodr ...... ugs and monoclonal antibodies.
@nl
prefLabel
Antibody-directed enzyme prodr ...... ugs and monoclonal antibodies.
@en
Antibody-directed enzyme prodr ...... ugs and monoclonal antibodies.
@nl
P2860
P1476
Antibody-directed enzyme prodr ...... ugs and monoclonal antibodies.
@en
P2093
Birgit Krewer
Lutz F Tietze
P2860
P304
P356
10.1111/J.1747-0285.2009.00856.X
P577
2009-07-29T00:00:00Z